

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview

2024/05/03 22:00:00	
Price	10.68 CAD
Difference	<div><div></div><div>-3.35% (-0.37)</div></div>

General attributes	
ISIN	CA0717341071
Symbol	BHC
Exchange	Toronto Stock Exchange
Currency	CAD
Sector	Other
Security type	Stock
Market cap (m)	2,755 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	10.67 CAD (500)
Ask (Ask size)	10.69 CAD (1,200)
Open	11.03 CAD
High	11.21 CAD
Low	10.59 CAD
Close (prev. day)	11.05 CAD
VWAP	10.847836 CAD
Volume (pcs)	341,631
Trading volume	3,705,957.11
Number of trades	2,167
Last size	300

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH COMPANIES INC.	<div><div></div></div>



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

on sector			
Date		Headline	Download
2024/04/26		Global Equity Ratings	<div><div></div></div>
2024/04/03		Global Equity Ratings	<div><div></div></div>
2024/03/13		Global Equity Ratings	<div><div></div></div>
2024/02/22		Global Equity Ratings	<div><div></div></div>
2024/02/14		Global Equity Ratings	<div><div></div></div>

Details

2024/05/03 22:00:00	
Price	10.68 CAD
Difference	<div><div></div><div>-3.35% (-0.37)</div></div>

General attributes	
ISIN	CA0717341071
Symbol	BHC
Exchange	Toronto Stock Exchange
Currency	CAD
Sector	Other
Security type	Stock
Market cap (m)	2,755 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	10.67 CAD (500)
Ask (Ask size)	10.69 CAD (1,200)
Open	11.03 CAD
High	11.21 CAD
Low	10.59 CAD
Close (prev. day)	11.05 CAD
VWAP	10.847836 CAD
Volume (pcs)	341,631
Trading volume	3,705,957.11
Number of trades	2,167
Last size	300

Performance and Risk			
	6m	1Y	3Y
Perf (%)	+9.62%	+10.50%	-72.07%
Perf (abs.)	+0.97	+1.05	-28.52
Beta	1.90	1.20	1.78
Volatility	39.39	53.19	72.44



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	11.84 CAD (427,201)
Ø price 30 days Ø volume 30 days (pcs.)	12.60 CAD (447,056)
Ø price 100 days Ø volume 100 days (pcs.)	11.69 CAD (349,697)
Ø price 250 days Ø volume 250 days (pcs.)	11.01 CAD (372,437)
YTD High date	15.43 CAD (2024/04/03)
YTD Low date	10.10 CAD (2024/01/03)
52 Weeks High date	15.43 CAD (2024/04/03)
52 Weeks Low date	7.56 CAD (2023/05/12)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/05/03	16:21	7.53 EUR	0.03	7
Toronto Stock Exchange	2024/05/03	22:00	10.68 CAD	3.71	2,167
Stuttgart	2024/05/03	19:26	7.343 EUR	0.00	14
SIX Swiss Exchange	2019/06/28	17:35	24.11 CHF	0.00	1
NYSE	2024/05/03	22:00	7.82 USD	26.93	16,530

	03					
Munich	2024/05/03	08:05	7.64	EUR	0.00	1
Frankfurt	2024/05/03	08:05	7.484	EUR	0.00	1
Duesseldorf	2024/05/03	08:10	7.479	EUR	0.00	1
Berlin	2024/05/03	08:06	7.489	EUR	0.00	1

Company profile

Company Logo



Contact Details

BAUSCH HEALTH COS. INC.

--

2150 St. Elzéar Boulevard West - H7L 4A8
Laval

Telefon: +1-514-744-6792

Fax: +

E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH
COMPANIES INC.



Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board

Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee
Seana Carson	Member of Executive Committee
Tom Vadaketh	Member of Executive Committee

Board of directors

John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Russel Robertson	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board
Thomas Ross	Member of Supervisory Board